摘要
骨髓增生异常综合征(MDS)是克隆性造血系统恶性肿瘤的异质集合,同时也是最常见的获得性成年人骨髓衰竭综合征。其主要特征为无效造血和易转化为急性髓系白血病。文章介绍第60届美国血液学会(ASH)年会上报道的MDS发病、预后的分子机制,以及针对目前已有的MDS疾病预后评分模型改进的最新进展。
Myelodysplastic syndromes (MDS) are a heterogeneous collection of clonal hematopoietic malignancies and the most common acquired adult bone marrow failure syndromes.They are characterized by ineffective hematopoiesis and predisposition to acute myeloid leukemia.This article describes the molecular mechanisms of the pathogenesis and prognosis of MDS reported in the 60th American Society of Hematology (ASH) Annual Meeting,as well as recent advances in the improvement of the existing prognostic scoring systems of MDS.
作者
杨洁
陈宝安
Yang Jie;Chen Baoan(Department of Hematology,Zhongda Hospital Southeast University,Key Medical Discipline of Jiangsu Province,Myelodysplastic Syndromes Institute of Southeast University,Nanjing 210009,China)
出处
《白血病．淋巴瘤》
CAS
2019年第3期129-131,共3页
Journal of Leukemia & Lymphoma
基金
江苏省医学重点学科(2010-2020)
江苏省科技厅医学重点项目(BL2014078).
关键词
骨髓增生异常综合征
分子机制
预后评分模型
Myelodysplastic syndromes
Molecular mechanism
Prognostic scoring system
